Paediatric Strategy Forum
for Medicinal Product Development of Epigenetic Modifiers in Children and Adolescents
23-24 January 2020
Wyndham Philadelphia Historic District Hotel, 400 Arch Street, Philadelphia, USA
PRESS RELEASE: Groundbreaking Childhood Cancer Collaborative Comes to the U.S. for the First Time
The first ACCELERATE Paediatric Strategy Forum in the US – a focus on Epigenetic Modifiers
th multi-stakeholder Paediatric Strategy Forum, organised by ACCELERATE with the support of the Alex’s Lemonade Stand Foundation and in collaboration with the European Medicines Agency (EMA) and with participation of the Food and Drug Administration (FDA) was held in Philadelphia on 23 and 24 January 2020 and focused on epigenetic modifiers in children and adolescents.
The specific aims of the Forum were:
to identify epigenetic targets or mechanisms of action relevant to paediatric cancers and
to define the landscape for paediatric drug development of epigenetic modifiers.
DNA methyltransferase inhibitors/hypomethylating agents and histone deacetylase (HDAC) inhibitors were largely excluded from discussion as the aim was to discuss those targets for which therapeutic agents are early in development.
Seventy two participants (in person) from both North America and Europe (academic experts, patient advocates from Children’s Cause for Cancer Advocacy, Coalition Against Childhood Cancer, Alex’s Lemonade Stand, KickCancer, Solving Kids’ Cancer and the Andrew McDonough B+ Foundation; EMA [including the Paediatric Committee] and FDA regulators) and representatives from 11 biopharmaceutical companies discussed the scientific rationale for the epigenome to be a therapeutic target across all paediatric malignancies.
A comprehensive overview of the scientific rationale for epigenetic modifiers in paediatric leukaemia, central nervous system tumours and solid tumours was presented as well as the pharmacological and clinical information on seventeen compounds being developed as epigenetic modifiers.
Conclusions of the Forum
The epigenetic landscape is an evolving field and is highly relevant to many paediatric cancers; the biology is elegant and new targets are emerging constantly. Targeting epigenetics is considered a very important therapeutic approach in paediatric malignancy, which has yet to achieve its full potential, as, many targets do not yet have drugs available.
A combination approach is critical for many epigenetic modifiers (e.g. EZH2 and EED) and exploration of the optimum combination should be underpinned by extensive preclinical research in advance of clinical translation.
The Forum greatly encouraged more extensive pre-clinical research. Eight classes of medicinal products were discussed and prioritised, based on the level of science to support early evaluation in children: menin, DOT1L, EZH2, EED, BET, PRMT5, LSD1 inhibitors and retinoic acid receptor alpha agonists. Menin inhibitors should be moved rapidly into paediatric development, in view of their biological rationale, pre-clinical activity and ability to fulfil an unmet clinical need.
A follow up multi-stakeholder meeting focusing on BET inhibitors will be held to define how to prioritise the multiple compounds in clinical development that may need to be evaluated in children and evaluate their specific roles. As epigenetic modifiers are early in development, there is a major opportunity to define the landscape of epigenetic modifiers in order that efficient and optimum plans for their evaluation in children and adolescents are developed. A detailed manuscript describing the conclusions of the Forum is in preparation.
With a support of: